|Reference : Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 d...|
|Scientific journals : Article|
|Human health sciences : Endocrinology, metabolism & nutrition|
|Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.|
|Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]|
|Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]|
|American Diabetes Association|
|Yes (verified by ORBi)|
|[en] Administration, Oral ; Chromans/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin Resistance ; Metformin/therapeutic use ; Randomized Controlled Trials as Topic ; Sulfonylurea Compounds/therapeutic use ; Thiazoles/therapeutic use ; Thiazolidinediones|
|[en] Insulin resistance is a major component of type 2 diabetes; therefore, an insulin sensitizer agent like the thiazolidinedione compound troglitazone is considered a very promising drug. Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. Additive antihyperglycemic effect may also be obtained by combining troglitazone and metformin. The antihyperglycemic effect of troglitazone as monotherapy is rather modest (reduction of HbA1c by 0.5-1.0%), but it appears to be somewhat greater when it is combined with other antidiabetic drugs. No double-blind studies have directly compared the activity of troglitazone with that of sulfonylureas or metformin. Troglitazone has been shown to exert additional beneficial effects on serum lipid profile and arterial blood pressure. It may be considered as a valuable alternative in insulin-resistant (obese and hyperinsulinemic) diabetic patients who appear to be the best responders to the drug. However, the efficacy of troglitazone is challenged by its safety profile, and the risk of hepatotoxicity still remains a major concern in clinical practice.|
There is no file associated with this reference.
All documents in ORBi are protected by a user license.